A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Clinical trial NCT06170489 · RECRUITING
Trial details
- NCT number
- NCT06170489
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-28
- Primary completion
- 2025-05-31
- Enrollment
- 185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.